Soleus Capital Management’s Immunovant IMVT Stock Holding History

Soleus Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.71M	Buy	252,000 +22,000	+10%	+$670K	0.33%	56
2026 Q1	$5.71M	Sell	230,000 -880,000	-79%	-$22.8M	0.23%	63
2025 Q4	$28.2M	Buy	+1,110,000	New	+$24.8M	1.04%	25
2024 Q4	–	Sell	-9,678	Closed	-$276K	–	95
2024 Q3	$276K	Sell	9,678 -242,222	-96%	-$7.14M	0.02%	86
2024 Q2	$6.65M	Sell	251,900 -12,750	-5%	-$363K	0.59%	55
2024 Q1	$8.55M	Sell	264,650 -52,400	-17%	-$1.91M	0.63%	49
2023 Q4	$13.4M	Sell	317,050 -82,549	-21%	-$3.04M	1.48%	22
2023 Q3	$15.3M	Buy	399,599 +226,000	+130%	+$5.11M	1.42%	25
2023 Q2	$3.29M	Buy	+173,599	New	+$3.24M	0.37%	60

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Soleus Capital Management's IMVT Position: Q2 2026 in Review

Soleus Capital Management increased its Immunovant (IMVT) stake by 9.6% in Q2 2026, buying an estimated $670K and bringing the position to 252,000 shares worth $9.71M. The position accounts for 0.33% of the portfolio, ranked #56.

Soleus Capital Management first reported a position in IMVT in Q2 2023 and has held it in 9 quarters since. The position peaked at $28.2M in Q4 2025. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Soleus Capital Management held 252,000 shares of Immunovant worth $9.71M as of Q2 2026.
Soleus Capital Management bought 22,000 Immunovant shares in Q2 2026, an estimated $670K.
Immunovant made up 0.33% of Soleus Capital Management's portfolio in Q2 2026, its #56 holding.
Soleus Capital Management first reported a position in Immunovant in Q2 2023 and has held it in 9 quarters since.
Soleus Capital Management's Immunovant position peaked at $28.2M in Q4 2025.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.